Curriculum Vitae
Veena Luthra, MD
Suburban Research Associates
107 Chesley Drive, Unit 4
Phone (610) 891-7200
Fax (610) 891-9699 Media, PA 19063
Email: vluthra@verizon.net
Education:
Residencies/Internship:
- 1999 - 2000 Chief Resident, Child / Adolescent Psychiatry
Eastern Pennsylvania Psychiatric Institute, Philadelphia
- 1998 - 2000 Child and Adolescent Psychiatry Resident
Eastern Pennsylvania Psychiatric Institute, Philadelphia
- 1995 - 1998 General Psychiatry Resident
Eastern Pennsylvania Psychiatric Institute, Philadelphia
- 1981 - 1985 General Psychiatry Resident
King Edward Memorial Hospital, Bombay, India
Medical School/Undergraduate
- 1980 - 1984 M. D. - Board Certified in Psychiatry
G.S. Medical College, Bombay, India
- 1976 - 1980 M.B.B.S. - Bachelor of Medicine / Bachelor of Surgery
Topiwala National Medical College, Bombay, India
Licenses and Certifications:
2001- American Board of Psychiatry and NeurologyBoard Certified Child and Adolescent Psychiatry, Certificate No. – 5065
2000 – Board Certified General Psychiatry, Certificate No. – 48070
2004 - Certified Clinical Trial Investigator by the Association of Clinical Research Professionals
Licensure :
1998 – Commonwealth of Pennsylvania, MD-065139-L
Professional Experience:
- May 2006- Present Principal Investigator/Sub-Investigator Suburban Research Associates
- Apr. 2004-2006 Principal Investigator and private practice Clinical Trial Specialists
- 2003-present Consultant Psychiatrist Community Council for Mental Health and Retardation
- 2003-present Consultant Psychiatrist Philadelphia School District
- 2000-Present Clinical Assistant Professor of Psychiatry Drexel University College of Medicine, Philadelphia
- 2003-2004 Principal Investigator Comprehensive NeuroScience, Inc.
- 2002-2003 Staff Psychiatrist Devereux Kanner Center Evaluation and treatment of children/adolescents and young adults dually diagnosed with severe developmental disabilities, mental retardation and complex psychiatric disorders
- 2000-2002 Inpatient Psychiatry Attending MCP Hahnemann University, Philadelphia Management and continuing certification of 14-16 child and adolescent patients in acute setting, multidisciplinary assessments and multimodel treatments of severe, complex patients with a wide range of psychopathology and developmental abilities
- 2000-2002 Outpatient Psychiatry Attending MCP Hahnemann University, Philadelphia Specialized Clinic for psychiatric evaluation, triage and treatment of children, adolescents and adults 1992-1995 Consultant Psychiatrist Psychological Medicine Hospital, Kuwait
Professional Affiliations:
- Eastern Pennsylvania Psychiatric Institute
- St. Christopher’s Hospital for Children
Publications:
- Luthra V: Book Review and Commentary: Multicultural / multiracial psychology, mestizo, perspectives in personality and mental health, Journal of Applied Psychoanalytic Studies, 2001, 3(4): 473-475.
- Luthra V: Pinniti NR, Musthaq M, Umapathy C, Yoder K, Levinson DF: Is akathisia associated with poor clinical response to antipsychotics during acute hospital treatment? General Hospital Psychiatry, 2000, 22(4): 276-280.
- Luthra V: Markov D, Ambrosini PJ: Does guanfacine cause hallucinations in children? Journal of Child and Adolescent Psychopharmacology, 1999, 9(4): 313-314.
Research
Major Depression
- A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily
Oral XXX (x-xx-xxx mg) Versus Placebo in Subjects with Major Depressive Disorder over an Eight-Week Treatment Period
- XXX Versus XXX and Placebo in the Treatment of Patients with Major Depression
- Open-Label, Long-Term study of XXX in children and adolescents with Major Depression
Attention Deficit/Hyperactivity Disorder
- A Randomized, Double-Blind, Placebo-Controlled, Parallel Group study of XXX in children with ADHD
- A Phase III, Multicenter, 18-month, Open-label Safety, Tolerability, and Efficacy Study of XXX in the Treatment of Adolescents Aged 13-18 with Attention Deficit Hyperactivity Disorder (ADHD)
- A 6-Month, Open-Label study of XXX in children with ADHD Long-Term, Open-Label, Safety study of XXX in pediatric patients with ADHD
- A Phase III, Randomized, Multi-Center, Double Blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of XXX in Adolescents Aged 13-17 with Attention Deficit Hyperactivity Disorder (ADHD)
Borderline Personality Disorder
- A Randomized Flexible Dose Double-Blind Comparison with Placebo. Efficacy and Safety of XXX in Patients with Borderline Personality Disorder
Bipolar
- Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of two fixed oral doses of XXX in the treatment of Child and Adolescent patients, ages 10-17 years with Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features
Generalized Anxiety Disorder
- XXX xx mg (or x mg) once daily in the treatment of generalized anxiety disorder. An open multicenter safety study of 5 months, including a 1 month drug-free follow- up period. Follow-up to studies 3013023 and 3013025
- XXX once Daily Compared with Placebo in the Treatment of Generalized Anxiety Disorder
Alzheimer’s Disease
- A Randomized double blind placebo-controlled trial to evaluate the efficacy and safety of XXX in subjects with mild cognitive impairment (MCI)
clinically at risk for development of clinically probable Alzheimer’s disease
- Open-label extension trial to assess the long -term safety of a controlled release formulation of XXX in the treatment of Alzheimer's Dementia
- A Prospective, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Effect Of XXX on the Time to Clinical Diagnosis of
Alzheimer’s Disease in Subjects with Mild Cognitive Impairment
- A Randomized, double-Blind Placebo-controlled, Parallel Group Phase II Study to Evaluate the Safety and Efficacy of XXX in Subjects with Mild to Moderate Alzheimer’s Disease
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Efficacy and Safety of XXX in Subjects with Mild to Moderate Alzheimer’s Disease-Important information Study.
- Phase III Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with XXX on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer’s Type
Panic Disorder
- An Open-Label Study to Assess the Safety and tolerability of XXX in the Treatment of Adolescents with Panic Disorder or Anxiety with Panic Attacks
- A Randomized, Double-Blind, Placebo-Controlled Study of XXX in the Treatment of Adolescents with a Primary Diagnosis of Panic Disorder
- A Randomized, Double-Blind, Placebo-Controlled Study of Continuation Treatment with XXX in the Treatment of Adolescents with a Primary Diagnosis of Panic Attacks
Schizophrenia
- A Multicenter, Randomized, Double-Blind, Placebo-controlled Study of Two Fixed Oral Doses of XXX in the treatment of Adolescent Patients with Schizophrenia
- A Randomized, Double-Blind Placebo Controlled Study of XXX Versus XXX in the Treatment of Schizophrenia in adolescents 13 to 17 years
Social Anxiety Disorder
- A Randomized, Double-Blind Comparison of XXX, XXX, and Placebo in the Treatment of Social Anxiety Disorder
Insomnia
- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Long-Term Safety and Efficacy of Two Dose Levels of XXX
in Adult Patients with Primary Insomnia
- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of Two Dose Levels of XXX in Elderly Patients with Primary Insomnia
- A Phase III, Double-Blind, Outpatient, Extension Study to Assess the Long-Term Safety of Two Dose Levels of XXX in Elderly Patients with Primary Insomnia
- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of XXX in Adults with Chronic Insomnia
- A Phase III, Open-Label, Fixed Dose Study to Determine the Safety and Long-Term Administration of XXX in Subjects with Chronic Insomnia
- A Phase III, randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of a Modified Release Formulation of XXX in Adult Primary insomnia
- A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Paralled-Group Efficacy and Safety Extension Study of XXX and XXX in the Treatment of Adult Outpatients With Primary Insomnia
Seasonal Affective Disorder
- A 7- Month, Multicenter, Randomized, Double-blind, Placebo-Controlled Comparison of xx-xxx mg/day of Extended-release XXX and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder followed by an 8 week Observational Follow-up Phase
Migraine
- Randomized, Double-Blind, Placebo-Controlled Study of Oral XXX xx mg, xxx mg and xxxx mg in the Acute Treatment of Migraines in Adolescents
Sexual Desire Disorder
- Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Trial of XXX in Female Patients with Hypoactive Sexual Desire Disorder in the United States
Cardiovascular
- A Randomized, Double-Blind-Controlled, Multicenter, Phase III Study of XXX in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein
Osteoporosis
- Prospective, Open-Label, Multi-Center, Two-Part study to investigate patient satisfaction with monthly dosed XXX in women with postmenopausal osteoporosis or osteopenia transitioned from Once-Weekly XXX or XXX
Antipsychotic
- Clinical Antipsychotic trials of Intervention Effectiveness (CATIE) NIMH sponsored study evaluating the effectiveness of atypical and conventional
antipsychotic medication
Proficient In The Following Adult Psychiatric Rating Scales:
Abnormal Involuntary Movement Scale (AIMS)
Barnes Akathisia Rating Scale
Beck Depression Inventory
Brief Psychiatric Rating Scale (BPRS)
Clinical Dementia Rating Scale
Calgary Depression Scale
Clinical Global Impression (CGI)
Hamilton Anxiety Scale (HAMA)
Hamilton Depression Rating Scale (HAMD)
Leibowitz Social Anxiety Scale (LSAS)
Mini Mental Status Examination (MMSE)
Mini International Neuropsychiatric Interview (MINI)
Montgomery and Asberg Depression Rating Scale (MADRS)
Positive and Negative Syndrome Scale for Schizophrenia (PANSS)
Simpson Angus Scale for EPS
Structured Clinical Interview for DSM-IV (SCID)
Structured Clinical Interview for DSM-IV Axis II Disorders (SCID II)
Yale Brown Obsessive Compulsive Scale (YBOCS)
Young Mania Rating Scale (YMRS)
Proficient In The Following Child And Adolescent Psychiatric Rating Scales:
ADHD Ratings –IV (DuPaul)
Children’s Depression Rating Scale (CDRS)
Children’s Depression Inventory (CDI)
Children’s Yale Brown Obsessive Compulsive Scale (C-YBOCS)
Conner’s Parent Rating Scale
Diagnostic Interview Schedule for Children (DISC)
Diagnostic Interview for Children and Adolescents (DICA)
Fear Survey Schedule for Children Revised (FSSC-R)
Multidimensional Anxiety Scale for Children (MASC)
Overt Aggression Scale (OAS)
Schedule for Affective Disorder and Schizophrenia in children (K-SADS)
State-Trait Anxiety Inventory for Children
Young Mania Rating Scale
|
